AlphAIAlphAI — Financial news for AI agents
tradingview.com$INGM

Ingram Micro set to join S&P SmallCap 600 following Viatris-Pacira deal

Ingram Micro (INGM) will replace Pacira BioSciences (PCRX) in the S&P SmallCap 600 on November 17, following Viatris' (VTRS) planned acquisition of Pacira. INGM shares rose 4% in extended trading.

Original reporting
tradingview.com
Published Nov 12, 2026, 5:47 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 7:37 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Ingram Micro set to join S&P SmallCap 600 following Viatris-Pacira deal — source image
Source · tradingview.com
Decision brief

The 30-second read

$INGMBullishHigh
01

Why it matters

Index inclusion is a catalyst for short‑term price appreciation and may trigger fund rebalancing.

02

Market read

The news provides a clear, actionable catalyst for INGM traders and modest implications for small‑cap index composition.

03

What to watch

Potential dilution from the upcoming Viatris‑Pacira deal could weigh on Pacira shareholders, indirectly affecting sentiment toward related distributors.

Relevance 7/10Novelty 7/10Timing: pre-market today

Background

The article announces Ingram Micro's upcoming inclusion in the S&P SmallCap 600, replacing Pacira BioSciences after Viatris' pending acquisition of Pacira.

Company-level read

Ticker impact

$INGMBullishHigh confidence
Context

Ingram Micro will replace Pacira in the S&P SmallCap 600, causing a ~4% share rise in extended trading.

Expected impact

upward pressure as traders price in the index inclusion

Evidence & confidence

Index inclusion typically attracts passive fund inflows and boosts visibility.

Market effects

Sector

Small‑cap technology distribution sector may see modest uplift as index rebalancing occurs.

Regional

U.S. small‑cap market could experience slight buying pressure from index fund adjustments.

Global

Limited to U.S. markets; no immediate global ripple effect.

Counterpoint

What could challenge this read

If the price rally is already priced in, the move could reverse once the index change is fully digested.

Key entities

  • Company
    Ingram Micro

    Distributor joining S&P SmallCap 600

  • Company
    Viatris

    Acquirer of Pacira BioSciences

  • Company
    Pacira BioSciences

    Being acquired, removed from index

Read at source← All news

StoryIngram Micro to replace Pacira in S&P SmallCap 600 after Viatris acquisition

Also covered by

1 outlet

Related articles

$VTRSMed

Viatris and Innovata seek leave to appeal court order on HIV drug tender

Viatris and Innovata seek to appeal a court ruling that invalidated their contracts to supply HIV drugs to South Africa, worth R1.67bn and R1.575bn respectively. The court found their manufacturing licenses had expired during the bidding process. Both companies argue their disqualification was unjustified due to pending license renewals and valid import licenses.

businessday.co.za
$VTRSHighAI 8/10

VTRS Q3 2026 deep dive: new product launches and Pacira acquisition shape outlook

Viatris reported Q3 2026 revenue of $3.75 billion, missing estimates by 1.3%, but beat EPS and EBITDA expectations. The company raised full-year guidance for revenue, EPS, and EBITDA. Growth was driven by higher-margin products and new launches, while supply chain issues impacted some regions. The pending acquisition of Pacira BioSciences is expected to enhance EBITDA and expand product offerings.

finance.yahoo.com